CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Tenofovir disoproxil fumarate/Emtricitabine +1 moredrug
Likely dose
Tenofovir disoproxil fumarate/Emtricitabine 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00414518
NCT00414518N/ACompleted
CompareCT.gov

An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States

University of Colorado, Denver·interventional·Posted Dec 21, 2006·Updated Feb 20, 2013

In Brief

A clinical study evaluating Tenofovir disoproxil fumarate/Emtricitabine and Lopinavir/Ritonavir for HIV Infections. Completed, enrolled 16 participants across 3 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the safety and effectiveness of an anti-HIV drug regimen followed by treatment interruption in people recently infected with HIV. This study will also compare the effects of a treatment regimen including treatment interruption with a treatment plan based on clinical indicators.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States, Zimbabwe
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 21, 2006
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.5 years ago

Interventions

Tenofovir disoproxil fumarate/Emtricitabinedrug

300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily

Lopinavir/Ritonavirdrug

Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily